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Technological progress within the last 15–20 years has enormously increased our knowledge 
about the molecular basis of cancer development, tumor progression, and treatment response. 
As a consequence, a vast number of biomarkers have been proposed, but only a small fraction 
of them have found their way into clinical use. The aim of this paper is to describe the 
specific demands a clinically relevant biomarker should meet and how biomarkers can be 
tested stepwise. We name this procedure the ―triple-R principle‖: Robustness, 
Reproducibility, and Relevance. The usefulness of this principle is illustrated with the marker 
TP53. Since it is mutated in a broad spectrum of cancer entities, TP53 can be considered a 
very promising marker. Thus, TP53 has been studied in detail but there is still no explicit 
consensus about its clinical value. By considering our own experience and reviewing the 
literature, we demonstrate that a major problem of current biomarker research is disregard of 
whether the biomarker is prognostic or predictive. As an example, it is demonstrated that 
TP53 is not a prognostic marker, but rather a purely predictive marker, and that disregard of 
this fact has made this otherwise strong biomarker appear as not being clinically useful so far. 
 
Graphical abstract 
Many biomarkers have been proposed for cancer, but only a small fraction of them are clinically 
useful. This paper describes the specific demands a clinically relevant biomarker should meet and 
how biomarkers can be tested stepwise. This is illustrated with the marker TP53, which has been 
studied in detail but for which there is still no explicit consensus about its clinical value. 
Introduction 
―Clinically useful prognostic and predictive markers are those developed with a specific 
clinical context in mind and tested and validated within that clinical context.‖
1
 In other 
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Currently, many biomarkers are proposed, but only a few find their way into routine clinical 
use. Here, we demonstrate that even prominent biomarkers are not properly evaluated. The 
analysis as to whether a marker has prognostic or predictive qualities has previously not been 
recognized as crucial information thus far and therefore is often omitted.  
TP53 is one of the most commonly mutated genes in cancer and was therefore considered a 
promising biomarker.
2,3
 The presence of a TP53 mutation is generally associated with poor 
prognosis for the clinical behavior of the cancer.
4
 Nevertheless, no coherent explanation for 
this phenomenon can be found in the literature.
4,5
 No clinically useful opinion has yet been 
formed about what a mutated TP53 really means for a patient’s course of disease or for its 
outcome.
4
 As a consequence, many papers refer to TP53 as a prognostic marker, while others 
label it a predictive marker.
6
 The impression is given that these two terms are often used as 
synonyms, although, especially in clinical oncology, there is a significant difference.  
The aim of this article is to point out possible pitfalls during the process of developing a 
putative molecular biomarker. For that purpose, the ―triple-R principle‖ is presented. This 
concept is a standardized, stepwise process to evaluate a biomarker for its clinical usefulness. 
By considering our own experience and reviewing the literature, we demonstrate that TP53, 
contrary to opinion, is not a prognostic marker but a purely predictive marker. It can be seen 
that neglecting proper clinical evaluation of the biomarker TP53 has generated a lot of 
confusion and prevented the routine clinical application of one of the most promising 
biomarkers known so far.  
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Biomarker studies evaluate the essential qualities of biomarkers. These evaluations need to be 
done stepwise in order to avoid misleading conclusions. The triple-R principle summarizes 
the qualities of a biomarker that have to be assessed stepwise in retrospective and prospective 
clinical studies. The studies have to be allocated to the three phases of biomarker evaluation. 
Results and conclusions from each phase are required to correctly progress to the next phase 
(Table 1). 
 
Phase I: Robustness of a biomarker 
Most putative biomarkers arise out of the observation that a certain variant can be found in 
cancer patients. To clarify whether this variant represents a potential biomarker, three 
questions have to be answered upfront in retrospective analyses. First, does this variant 
exclusively occur in cancer? (= specificity of the marker in cancer cells or patients); second, 
in which types of cancer and how frequently does this variant occur? (= prevalence of the 
biomarker in cancer patients or with cancer subtypes); and third, does the biomarker status 
indicate cancer or affect the course of the disease, and if so, how? (= hypothesis, how the 
marker works). By answering the last of these questions, one can acquire an idea of whether 
the marker has diagnostic properties (= indicating cancer) or is influencing a patient’s 
survival. Thus, rRobustness describes the basic characteristic features of a biomarker and 
gives an idea of possible implications of the marker status. Assessment of a marker’s 
robustness can be done in retrospective phase I biomarker studies. 
 
Robustness of TP53. It has been consistently demonstrated that TP53 mutations can be 
found in all types of cancer, with an overall prevalence of 50%.
2
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prevalence among currently established cancer biomarkers (e.g., KRAS, B-raf, EGFR, etc.).
4
 
TP53 mutations are also highly specific for cancer, meaning that the mutations do not occur 
in normal cells. As the clinical value of a marker is directly related to its prevalence and its 
particular specificity, TP53 appears as the most promising from that point of view. Finally, 
besides its diagnostic properties (not covered in this article), the TP53 gene has been 
recognized as the gatekeeper for many cellular processes, such as the cell cycle, apoptosis, 
and many more.
7
 Therefore, numerous hypotheses describe that TP53 most likely affects the 
course of a malignant disease. How the marker actually works is still under discussion and 
lacks proper investigation.  
 
Phase II: Reproducibility of a biomarker  
A biomarker will be considered clinically useful if the biomarker evaluation delivers 
clinically reproducible results. We postulate that in biomarker research, reproducibility 
depends on two things: knowledge of the marker type and the availability of a standardized, 
sensitive marker test. These issues have to be assessed in phase II biomarker studies, which 
should be carried out retro- or prospectively. 
 
Knowledge of the marker type. If a marker appears to be associated with a cancer patient’s 
survival, it is crucial to know why. The recognition of the biological activities of a marker 
provides initial ideas and is able to serve as a basis for the marker hypothesis. In principle, a 
marker can affect survival of a cancer patient because it is either prognostic or predictive. Not 
least because ―predictive‖ and ―prognostic‖ are frequently misused as synonyms, the 
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a marker ―predicts a prognosis‖ demonstrates that there might also be a semantic problem 
involved.  
It is important to be aware that a prognostic marker predicts the course of a disease, that is, 
freedom or relapse of the disease. In contrast, a predictive marker predicts the efficacy of 
specific treatments, that is, response to a treatment or treatment failure. If the explicit 
definition of the marker type is missing, a marker may be used inappropriately, which will 
generate inconsistent results in clinical biomarker studies. At worst, due to the inconsistent 
results, the marker will be classified as clinically not useful.  
What makes it difficult is that both types of markers, prognostic and predictive, may affect 
survival. Therefore, it is important to be aware that they answer different questions in cancer 
cohorts. Indeed, the underlying scientific knowledge for the marker type is crucial for 
planning and interpreting clinical biomarker studies.
8
  
A prognostic marker relates to the natural history of a disease and objectively predicts the 
patient’s overall outcome.
9,10
 Prognostic markers are used to estimate risk. They are 
independent of therapy and are therefore unable to predict response to therapy.
9,10
 Thus, we 
find as a rule that a prognostic biomarker has to predict survival of cohorts in the absence of 
treatment. In contrast, a predictive marker is able to objectively predict the effect of a certain 
treatment and can be used to select a particular treatment over another.
9,10
 Thus, we find as a 
rule that the clinical evaluation of a predictive marker has to be connected to a treatment.  
The influence of the marker status on the treatment effect is usually described as an 
interaction, and both quantitative and qualitative interactions can be distinguished.
11 
If all 
patients (biomarker-negative as well as biomarker-positive) benefit from a certain treatment, 
but one marker group derives a greater benefit than the other, this phenomenon is referred to 
as a quantitative interaction.
9
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from a specific therapy while biomarker positive patients experience no advantage or even a 
disadvantage from this treatment, this is referred to as a qualitative interaction.
9
 As a rule, a 
qualitative interaction gives rise to dramatically different treatment effects for marker-
positive and -negative patients. Furthermore, the presence of an unrecognized qualitative 
interaction will always worsen the overall effect of a treatment in a clinical trial. Qualitative 
interactions have been rarely described in marker research so far.  
While the prognostic marker type can be simply determined by analyzing the marker in the 
context of an untreated cohort (which might not always be feasible nowadays), determination 
of a predictive marker type is more difficult as it is connected to specific treatments. 
Additionally a biomarker might show its predictive ability for some treatments but not for 
others.  
 
The marker type of TP53. Recently, two clinical studies have been published that qualify 
for determining the marker type of TP53 because both studies included untreated control 
arms.
12,13
 Both studies revealed that the TP53 status did not affect survival in the untreated 
patients. This strongly suggests that TP53 is not prognostic (Fig. 1B). Furthermore, in cohorts 
treated with certain chemotherapies, TP53 was often found to be associated with survival, 
which indicates that TP53 is a predictive marker.
12,14–17
 
Although the number of patients was quite small, the University of Vienna p53 Research 
Group recently published a study whose design was qualified to demonstrate the absence of 
any prognostic but the presence of a strong predictive value of TP53 in a single study for the 
first time.
12
 In this study, a homogenous cohort of patients with operable colorectal liver 
metastases were treated either with chemotherapy (5-flurouracil and oxaliplatin) followed by 
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related to survival, whereas in the group of patients treated with preoperative chemotherapy 
and subsequent surgery, a dramatic survival difference associated with TP53 status was 
noticed.
12
 Strikingly, the chemotherapy effect was the opposite in the chemotherapy patients 
with and without TP53 mutations. Overall, the TP53-mutated patients who received 
preoperative chemotherapy had the poorest outcome, even worse than the patients treated 
with surgery only (irrespective of their TP53 status). The TP53-normal patients treated with 
the respective preoperative chemotherapy had a significantly better outcome, which was also 
superior to the outcome of the surgery only patients (irrespective of their TP53 status). Thus, 
a dramatically different treatment effect for TP53-mutated and TP53-normal patients was 
demonstrated, suggesting the presence of a qualitative interaction for the first time. The latter 
was supported by the demonstrated hazard ratio of 5.5 to the disadvantage of the 
chemotherapy-treated patients with TP53 mutations (Fig. 1).  
 
Standardized, sensitive marker tests. A clinically useful biomarker requires a reproducible 
method to assess the marker status (i.e., normal versus mutated gene status). In other words, a 
standardized marker test has to be available with adequate, proven sensitivity and specificity. 
If different tests are available, as for TP53 worldwide, it has to be proven that they deliver 
identical results. In clinical practice, however, standardization of marker tests is only raised 
as a topic when a marker is considered as clinically useful. Thus, initially marker research is 
done with nonstandardized methods, limiting the comparability and significance of the 
research results.  
 
Marker tests for TP53. p53 immunohistochemistry (IHC) is an ideal example to 
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deduce the mutational status of TP53, even though it is well known that p53 IHC and TP53 
DNA sequencing results can differ dramatically.
5,17–19
 Besides the problem of false negative 
and false positive IHC results (= lack of specificity), the method is not standardized, meaning 
that different antibodies with varying degrees of sensitivity are in use.
9,13,17,20,21
 Additionally, 
it is noteworthy that the concordance rates between IHC and sequencing differ between 
tumor entities. This might derive from different TP53 mutation patterns present in different 
tumor entities. This demonstrates that IHC is detecting different TP53 mutations 
unequally.
22,23
 However, for a predictive marker, the highest levels of sensitivity and 
specificity of the marker test are required because a predictive marker is used to select an 
appropriate treatment.  
In recent years, DNA-based marker tests have gained increasing importance. We like to 
assume that a gene mutation detected at the DNA level is either present or not and that this 
fact should not change, no matter when or how often the test is run. However, there are 
various different DNA sequencing technologies on the market and their strategic emphases 
are different; most often, the focus is on high throughput rather than on gene-specific 
sensitivity.  
Some technologies—like next-generation sequencing—generate numerous sequencing 
artifacts,
24,25
 which can be identified by multiple testing. Such platforms offer the 
simultaneous testing of hundreds of genes or the detection of whole genome mutations of a 
patient. But, who is able to handle the vast amount of data properly? How will we correlate 
thousands of results with a certain cancer type, a certain cancer stage, a certain course of 
disease, or a certain response to a certain treatment? We will possibly never have enough data 
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Phase III: Relevance of a biomarker 
As soon as the marker type is clarified and a sensitive, standardized marker test is 
established, both as a result of phase II biomarker studies, the therapeutic relevance of a 
biomarker can be finally assessed. The magnitude of the effect of a biomarker needs to be 
evaluated in a phase III biomarker study comparing standard treatment versus biomarker-
adapted treatment in a prospective randomized design.
11
 For the implementation of the 
biomarker in the trial, knowledge of the marker type is crucial (i.e., whether the biomarker is 
prognostic or predictive).  
For the clinical validation of a prognostic marker, the marker should ideally be assessed in an 
untreated cohort; if not, then in a cohort treated with surgery only. A clinically relevant 
prognostic biomarker will split the cohort into two or more groups with significantly different 
outcomes. A prognostic marker is of clinical relevance if it can be demonstrated that its effect 
is independent of other prognostic parameters already established (using a multivariate 
analysis). As a consequence, stratification for the status of the validated, independent 
prognostic marker is mandatory for upcoming clinical trials or for reanalysis of published 
trials. 
For the clinical validation of a predictive marker, an interaction between the marker and the 
effect of a certain treatment has to be demonstrated. For that purpose, the Marker by 
Treatment Interaction Design has been suggested by Sargent et al.
11
 This design splits the 
study population into two groups depending on the particular marker status (marker-negative 
and marker-positive patients). Subsequently, each group is randomized into two different 
treatment arms (standard versus experimental) and analyzed separately. The advantage of this 
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between the marker status and the treatment allocation can be tested.
11
 However, this design 
is not ideal for testing a panel of markers.
11
 
A predictive marker is of clinical relevance if a significant interaction between the marker 
status and the effect (preferably on survival) of the treatment can be demonstrated. As a 
consequence, certain treatments can be preferably or even exclusively applied to patients with 
the appropriate marker status. Conversely, if it is demonstrated that a certain marker status 
interacts with a certain treatment in a disadvantageous way, this treatment can be avoided.  
 
Relevance of TP53. For the biomarker TP53, the first prospective randomized biomarker 
trial has been conducted by the University of Vienna p53 Research Group.
27
 The aim of the 
p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer 
(PANCHO) trial (ClinicalTrials.gov identifier: NCT00525200) is to validate the biomarker 
TP53 as a marker potentially predicting the effect of neoadjuvant chemotherapy in 
esophageal cancer patients. The trial has been designed according to the Marker by Treatment 
Interaction design (Fig. 2). A standardized marker test (Mark53® test), which has been 
assessed in phase II biomarker trials (Table 2), is used and validated in that trial. The trial is 





Only a few biomarkers find their way into clinical use. In this paper, the lack of systematic 
evaluation is identified as a major issue for biomarkers. As an answer to this problem, the 
triple-R principle‖ (Robustness, Reproducibility, and Relevance) is introduced as a 
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procedure is demonstrated with the well-known marker TP53, for which clinical research has 
so far failed to demonstrate any clinical utility. Besides its diagnostic properties, there is still 
no consensus as to whether the marker is useful to prognosticate the course of disease or to 
predict treatment response in cancer patients.  
Twenty years of systematic clinical evaluation of the marker TP53 by the Medical University 
of Vienna p53 Research Group has culminated in the conclusion that TP53 is not a prognostic 
but a predictive marker. We believe that the community’s disregard of the marker type of p53 
has generated a lot of confusion in clinical p53 research, which has prevented the marker 
from clinical use. As a consequence, the development and validation of standardized marker 
tests was not tackled.  
We contend that the reproducibility of results in clinical biomarker research crucially depends 
on the knowledge of the marker type of a biomarker. We consider the omission of initial 
determination of the marker type as a serious mistake in clinical biomarker research. 
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Figure 1. Phase II biomarker study design to assess the marker type of TP53. Prospective 
study randomized patients either received (A) neoadjuvant chemotherapy followed by 
surgery or (B) surgery alone for operable colorectal liver metastases. TP53 marker analysis 
was done retrospectively from surgical specimens. (A) In the presence of neoadjuvant 
chemotherapy, a mutated TP53 predicts a dramatic survival disadvantage (hazard ratio of 
5.5), while a normal TP53 predicts survival benefit. The opposite treatment effect is predicted 
by the respective marker status (mutated or normal), indicating the presence of a qualitative 
interaction between marker status and treatment effect. (B) In the absence of chemotherapy 
(surgery-only group), the TP53 status is not associated with overall survival, and thus is not 
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Figure 2. Design of a phase II biomarker trial for the validation of TP53. The Marker by 
Treatment Interaction clinical trial design for the p53-Adjusted Neoadjuvant Chemotherapy 
for Potentially Resectable Esophageal Cancer (PANCHO) trial (ClinicalTrials.gov identifier: 
NCT00525200). Originally published in Ref. 28. 
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Table 1. The triple-R principle for systematic clinical evaluation of a biomarker  
  
















Specificity of the marker in populations with 
and without cancer 
 























Marker type (diagnostic, prognostic, or 
predictive) 
 
Marker test (sensitivity and specificity, e.g., 




















Confirm magnitude of effect(s)  
 
Confirm marker type 
 
Confirm effect is independent of known 











NOTE: A biomarker’s Robustness is determined by the specificity, the prevalence, and the 
hypothesis of the marker. Reproducibility is dependent on knowledge of the marker type—
whether the marker is diagnostic, prognostic, or predictive—and the availability of 
standardized, sensitive marker tests. Relevance is assessed in prospective randomized phase 
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Table 2. Systematic clinical evaluation of the biomarker TP53: The triple-R principle 
illustrated by 20 years of clinical research at the Medical University of Vienna p53 Research 
Group 
 
Phase I: Robustness 
 
Year Reference Title   
1994 29 Carcinogen-specific mutations in the p53 tumor 
suppressor gene in lung cancer  
Prevalence Retrospective 
2004 30 p53 analysis in gallbladder cancer: comparison of 
gene analysis versus immunohistochemistry  
Prevalence Retrospective 
1996 31 Molecular genetic differentiation between 
primary lung cancers and lung metastases of 
other tumors   
Specificity Retrospective 
2006 32 Genetic detection of lymph node 
micrometastases: a selection criterion for liver 
transplantation in patients with liver metastases 
after colorectal cancer  
Specificity Retrospective 
1999 33 The TP53 genotype but not immunohistochemical 
result is predictive of response to cisplatin-based 





2000 34 TP53 mutation and p53 overexpression for 
prediction of response to neoadjuvant treatment 




2002 17 TP53 genotype but not p53 immunohistochemical 
result predicts response to preoperative short-






Phase II: Reproducibility 
 
Year Reference Title   
2008 35 Growing clinical evidence for the interaction of 
the p53 genotype and response to induction 






2014 16 The biomarker TP53 divides patients with 
neoadjuvantly treated esophageal cancer into 
two subgroups with markedly different outcomes. 





2015 15 TP53 mutational status and prediction of benefit 
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cancer patients 
2015 12 Assessing the TP53 marker type in patients 
treated with or without neoadjuvant 
chemotherapy for resectable colorectal liver 







Phase III: Relevance 
 
Year Reference Title   
2010 36 PART1––p53 adapted preoperative radiotherapy 







2018 28 Pancho trial (p53-adapted neoadjuvant 
chemotherapy for resectable esophageal cancer) 
completed––mutation rate of the marker higher 
than expected 
Magnitude 
of 
effect/marke
r test 
Prospective 
randomized 
 
 
 
